RJFSA
OCUL icon

Raymond James Financial Services Advisors’s Ocular Therapeutix OCUL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$841K Buy
96,644
+23,893
+33% +$197K ﹤0.01% 2278
2024
Q2 		$498K Buy
72,751
+18,567
+34% +$115K ﹤0.01% 2541
2024
Q1 		$493K Sell
54,184
-7,856
-13% -$55.8K ﹤0.01% 2528
2023
Q4 		$277K Sell
62,040
-12,361
-17% -$36.6K ﹤0.01% 2794
2023
Q3 		$234K Buy
74,401
+23,637
+47% +$96.7K ﹤0.01% 2830
2023
Q2 		$262K Buy
50,764
+36,009
+244% +$214K ﹤0.01% 2753
2023
Q1 		$77.8K Buy
14,755
+1,700
+13% +$8.07K ﹤0.01% 3082
2022
Q4 		$36.7K Sell
13,055
-21,818
-63% -$72.2K ﹤0.01% 3106
2022
Q3 		$145K Buy
34,873
+4,045
+13% +$20.4K ﹤0.01% 2931
2022
Q2 		$124K Buy
30,828
+9,244
+43% +$34.9K ﹤0.01% 2982
2022
Q1 		$107K Sell
21,584
-45,218
-68% -$251K ﹤0.01% 3103
2021
Q4 		$466K Buy
66,802
+43,073
+182% +$334K ﹤0.01% 2418
2021
Q3 		$237K Sell
23,729
-1,864
-7% -$20.9K ﹤0.01% 2855
2021
Q2 		$363K Sell
25,593
-406
-2% -$6.17K ﹤0.01% 2592
2021
Q1 		$427K Buy
25,999
+1,109
+4% +$21.4K ﹤0.01% 2396
2020
Q4 		$515K Buy
24,890
+3,876
+18% +$57.6K ﹤0.01% 2127
2020
Q3 		$160K Sell
21,014
-28,605
-58% -$237K ﹤0.01% 2597
2020
Q2 		$413K Buy
49,619
+34,143
+221% +$226K ﹤0.01% 2030
2020
Q1 		$77K Buy
+15,476
New +$76.4K ﹤0.01% 2274

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Raymond James Financial Services Advisors's OCUL Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Ocular Therapeutix (OCUL) stake by 33% in Q3 2024, buying an estimated $197K and bringing the position to 96,644 shares worth $841K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Raymond James Financial Services Advisors first reported a position in OCUL in Q1 2020 and has held it in 19 quarters since. 168 funds tracked by Wall St. Rank hold OCUL as of Q3 2024.

  • Raymond James Financial Services Advisors held 96,644 shares of Ocular Therapeutix worth $841K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 23,893 Ocular Therapeutix shares in Q3 2024, an estimated $197K.
  • Ocular Therapeutix made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2278 holding.
  • Raymond James Financial Services Advisors first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 19 quarters since.
  • 168 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.